Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

The semaglutide dosing chart below shows the dosing schedule ... to try a different GLP-1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide) are two ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... drug Mounjaro and weight loss medicine, Zepbound. However, in mid ...

You can use this BMR calculator ... weight loss medications, like GLP-1s, into your routine can also help if diet and exercise alone aren’t cutting it. Drugs like Wegovy (semaglutide) and ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...